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Acute ingestion of ethanol induces vasodilation and 
swelling of respiratory mucosa; it depresses respiratory cen-
ters resulting in hypotonia of oropharyngeal dilator muscles 
and inducing or aggravating sleep apnea. However, no asso-
ciation between the sleep apnea syndrome (SAS) and Alcohol 
Use Disorders (AUD) has been demonstrated. 
Introduction 
Sixty eight patients diagnosed as having SAS by 
polysomnography over a 6-month period were evaluated for 
the presence of AUD using the Michigan Alcoholism Screen-
ing Test (MAST) and an alcohol consumption history ques-
tionnaire. The prevalence of AUD was obtained by including 
both the positive MASTs and/or with admitted hazardous con-
sumption known to correlate with significant physiologic risk 
(5 or more standard drinks per day on a regular basis). The 
correlation between moderate and severe SAS known to be 
associated with increased risk for mortality (Apnea Index > 
20), was then evaluated with respect to presence or absence of 
AUD. 
The prevalence of AUD in the SAS patients as defined by 
MAST alone was 22% (15/68), a figure which correlates with 
the prevalence found in other studies of in- and outpatient 
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... double jeopardy 
cohorts. Twelve sleep apnea patients (18%) admitted that they 
consumed hazardous amounts of alcohol. The prevalence of 
AUD, using a positive MAST and/or admitted hazardous con-
sumption, was 31% (21/68). Eighty six percent (18/21) of the 
patients with AUD were found to have an apnea index of 20 
or greater, indicating a high mortality risk. AUD and high 
mortality risk sleep apnea were in significant correlation (N = 
68, r = 0.24, p < 0.05). 
Our study demonstrates a significant correlation between 
AUD and SAS, even in the absence of acute alcohol ingestion 
immediately prior to the polysomnographic test. In addition, 
the correlation between AUD and SAS severity suggests that 
the morbidity seen in both AUD and SAS may be related to 
the same pathophysiologic mechanism. 
Background 
The effect of alcohol on sleep is well known. Acute alcohol 
ingestion disrupts the normal sleep pattern by reducing sleep 
latency and increasing wakefulness in the last half of the 
night1• Abnormal sleep patterns occur in alcoholics, even after 
prolonged sobriety, because of the effects of chronic alcohol 
toxicity on sleep centers2•3• 
The relationship between acute alcohol ingestion and sleep 
apnea has also been investigated. Taasan et al demonstrated 
that 2 ml/kg of alcohol consumed 1 hour prior to bedtime 
induced apneic episodes (cessation of breathing at the nose 
and mouth for 10 seconds or more4) in normal subjects5• 
Scrima and colleagues found similar results in both normal 
subjects, as well as in individuals diagnosed with the SAS 
after 3 oz of 80-proof alcohol6• Alcohol induces apnea through 
both central and peripheral mechanisms. Acute ingestion of 
ethanol induces vasodilation and swelling of respiratory 
mucosa and depresses respiratory centers, resulting in hypoto-
nia of oropharyngeal dilator muscles and inducing or 
aggravating sleep apnea7•8• Peripherally, alcohol causes vasodi-
lation resulting in pharyngeal edema'. 
There is also a possible link between chronic heavy alcohol 
ingestion and sleep apnea. Vitiello and colleagues demonstrat-
ed a high prevalence of nocturnal hypoxic episodes in a popu-
lation of recovering alcoholics8• In addition, the severity of the 
alcohol abuse was found to correlate with the level of noctur-
nal hypoxia9•10• It was suggested that the mechanism was sleep 
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apnea, however these patients were not tested by polysomnog-
raphy. 
The relationship between chronic alcohol use and the SAS 
(5 or more apneic episodes per hour of sleep•) is important 
because both diseases result in significant morbidity. In fact, 
the sequelae of both diseases include hypertension, arrhyth-
mias, depressive symptoms, cardiac disease, cerebrovascular 
accidents and, most importantly, death. He et al demonstrated 
that sleep apnea patients with an apnea index (AI) > 20 had 
significantly greater mortality than those with an AI < 20". 
The correlation between SAS severity and the mortality in 
alcoholic SAS patients has not been studied. 
Our study investigates 2 aspects: (1) What is the preva-
lence of AUD in patients diagnosed with SAS by poly-
somnography? and (2) is AUD related to the severity of SAS? 
The term "Alcohol Use Disorder" (AUD) was chosen to con-
form with the criteria for alcohol abuse and/or alcohol depen-
dence found in the third edition of the Diagnostic and Statisti-
cal Manual of the American Psychiatric Association (DSM 
III-R)t2. 
Methods 
Sixty eight patients presenting to the Kuakini Medical Cen-
ter Sleep Laboratory for polysomnography over a 6-month 
period were diagnosed as having SAS. These patients were 
evaluated for a possible associated AUD, using the Michigan 
Alcoholism Screening Test (MAST). MAST is a weighted, 
25-item questionnaire, which screens for the presence of alco-
holism when 5 or more points arc calculated on the basis of 
positive responses13 • 
The results of MAST were then correlated with the alcohol 
consumption history obtained from the sleep laboratory ques-
tionnaire developed by Laughton Miles 1'. The alcohol con-
sumption questions solicit information concerning the type of 
alcoholic beverage consumed and the pattern of usc as mea-
sured by both quantity and time frame. Individuals with 
admitted consumption of 5 or more standard drinks on a regu-
lar basis (daily or on weekends) were considered to have a 
possible AUD because Sanchez-Craig and colleagues demon-
strated that this pattern of "hazardous consumption" results in 
a significant morbid risk to individuals15 • 
Finally, the relationship between the severity of AUD and 
of SAS was examined by comparing MAST results and the 
presence or absence of hazardous consumption of alcohol. 
The severity of SAS was defined by an apnea index of < 20 
versus ::::: 20. An apnea index of 20 is thought to require treat-
ment because of the increased risk of death as a consequence. 
Such patients are generally considered to be candidates for 
treatment with continuous positive airway pressure because it 
has been demonstrated that the incidence of mortality is 
reduccd11 • 
Results 
The average age of patients referred to the sleep laboratory 
was 48 years, with a range of 20 to 73 years. The prevalence 
of MAST positive sleep apnea patients was 22% (15/68). 
None of the 12 female patients were screened positive on 
MAST, whereas 15 of 56 males were MAST positive for a 
prevalence of 27%. Fourteen individuals evaluated by the 
sleep laboratory did not complete MAST; the participation 
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TABLE 1 
Relationship between admitted hazardous 
consumption and MAST scores 
POS. NEG. 
MAST MAST TOTAL 
HAZARDOUS Present 6 6 12 
CONSUMPTION* 
(Number of Absent 9 47 56 
Patients) 
* Hazardous consumption is the admitted consumption of 
5 or more standard drinks on a regular (daily or on 
weekends) basis. 
TABLE2 
Relationship between alcohol use disorders 
and sleep apnea syndrome 
SEVERITY 
OFSAS AGE 
Apnea Index 
<20 >20 Total Mean 
(No. of Pts.) No. (SO**) 
Present 3 18 21 46.8 
(7.7) 
AUD* 
Absent 18 29 47 48.5 
(12.8) 
* Patients with Alcohol Use Disorders (AUD) 
are MAST positive and/or admit to 
Hazardous Consumption. 
**Standard Deviation 
rate was 85%, therefore. 
Twelve sleep apnea patients (18%) admitted to regular haz-
ardous consumption of alcohol. Six of the 15 MAST-positive 
patients did not complete the alcohol consumption question-
naire. The correlation between MAST scores and reports of 
hazardous consumption was significant (N = 68, r = . 27, p < 
0. 05), as shown in Table l. 
Since our study addressed the impact of both chronic alco-
hol abuse and dependence on sleep apnea, the number of SAS 
patients with positive MASTs and/or hazardous consumption 
were combined. This produced a combined prevalence of 31% 
(21/68). The combined prevalence in males was even higher 
38% (21/56); none of the females screened positive on 
MAST or indicated hazardous consumption. 
Using an Apnea Index (AI) of 20 as a cut-off score to eval-
uate risk for mortality, 86% (18/21) of the patients with AUD 
were found to have a high mortality risk related to their sleep 
apnea (Table 2). AUD and high mortality risk sleep apnea 
were significantly correlated (N = 68, r 0. 24, p < 0. 05) . 
Discussion 
The prevalence of AUD in the SAS population as deter-
mined by MAST was 22%, a figure which compares with the 
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prevalence found in other studies of in- and outpatient medical 
populations16.17•18• However, MAST did not identify 9% (6/68) 
of patients with admitted hazardous consumption. The defini-
tion of AUD in the DSM III-R includes individuals who 
knowingly consume alcohol in the face of medical problems 
exacerbated by the consumption12• In the sleep laboratory, SAS 
patients with hazardous consumption would fit this definition. 
Although there was a significant correlation between MAST 
and the presence or absence of hazardous consumption, the 
9% false negative rate was greater than in a study by Cyr and 
Wartman, who found that in an ambulatory practice popula-
tion only 7 of 242 individuals were heavy drinkers who did 
not screen positive on MAST19• 
MAST might not identify certain hazardous drinkers 
because the weighted items on MAST generally screen for 
social consequences of alcoholism, which not all alcoholics 
develop. The medical consequences that are picked up by 
MAST include only cirrhosis or an identification by physi-
cians that alcohol is the etiology of medical complaints. How-
ever, previous studies have demonstrated low physician recog-
nition of alcoholism1'·1a.20• Since the medical consequences of 
alcoholism and sleep apnea (sleep disturbance, depressive 
symptoms, hypertension, arrhythmias, etc) are almost identi-
cal, symptoms may not have been attributed to the presence of 
AUD. 
Our study also found that 40% of MAST positive patients 
did not report hazardous consumption. This discrepancy is 
most likely related to the sleep laboratory policy of advising 
SAS patients to discontinue drinking. Patients referred to the 
sleep laboratory are generally quite symptomatic with their 
sleep disturbance and are routinely informed that alcohol can 
worsen their symptoms. In addition, physicians who refer 
patients for sleep studies commonly give the patient the same 
caveat because of the association between alcohol ingestion 
and apneic events. Thus, at the time the alcohol consumption 
portion of the sleep questionnaire was completed, it was 
unlikely that patients would report hazardous consumption. 
Lee and DeFrank point out that MAST may not be an accurate 
reflection of current alcohol consumption and may misidentify 
a person who no longer consumes alcohoJ21• However, since 
our study evaluates the possible toxic effect of chronic alcohol 
consumption, MAST is a useful tool to identify subjects who 
may have had a past history of hazardous drinking. 
To get a more accurate indication of the prevalence of 
AUD in SAS patients, it is necessary to add the number of 
MAST positive patients to the number of MAST negative 
patients who indicated hazardous consumption. This yields a 
combined prevalence of 31%, 38% in males alone. The high 
prevalence in males is important because both AUD and sleep 
apnea are predominantly male diseases. 
The 31% combined prevalence of AUD in SAS patients 
found in this study suggests an association between AUD and 
sleep apnea. This association cannot be explained on the basis 
of acute ingestion of alcohol because patients at the sleep lab-
oratory who ingested alcohol prior to the visit were generally 
not evaluated by polysomnography. In addition, sleep apnea 
patients with AUD were more likely to have an AI of> 20, 
indicating there may be an association between AUD and the 
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severity of SAS. 
In our study, a sub-sample of 17 of the 68 SAS identified 8 
with AUD. None of the 8 had been referred by their physi-
cians for alcohol counseling, although 4 had discontinued or 
cut down their drinking. As in other studies demonstrating 
low rates of recognition by physicians and referral for alco-
holism treatment17•1a.20, the concern is that complete evaluation 
of SAS patients should include screening and referral for 
AUD. This is because acute alcohol ingestion aggravates SAS 
and patients with AUD are unlikely to quit drinking for pro-
longed periods without the help of a recovery program. The 
results of our study suggest that patients with AUD are more 
likely to present with an AI of 20 or more; He et al demon-
strated this degree of severity carries a significant risk for 
mortalityu. Therefore, intervention in AUD is as important as 
therapy in sleep apnea. 
The 31% combined prevalence of AUD in SAS patients 
and the likelihood of having an AI of 20 or more, suggests 
that the toxicity of chronic alcohol ingestion plays a role in the 
development of morbidity and mortality in sleep apnea. As a 
corollary, the morbidity associated with alcoholism may be 
attributed in part to the medical sequelae of sleep apnea 
(arrhythmias, hypertension, etc), especially since these are fre-
quently found in alcoholic patients. This raises the question 
whether sleep apnea may be a common but undiagnosed prob-
lem in chronic alcoholics. The finding by Vitiello and col-
leagues of nocturnal hypoxia in abstaining alcoholics suggests 
this to be the case9•10• Further studies are needed in order to 
evaluate the association between alcoholism and sleep apnea. 
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worse off. No one can say that change won't be coming. 
Those who don't like the RBRVS and the limits on balance 
billing should consider the alternatives: mandatory assign-
ment, MD-DRGs, and fees set by the government without any 
professional input. The RBRVS gives the profession a voice, 
and it enables us to ward off more objectionable measures. 
Finally and most importantly, the RBRVS is good for our 
patients. It will increase the emphasis on preventive care and 
on evaluating and managing their treatment, and decrease the 
emphasis on costly high-tech services. It also will help 
improve access to care in underserved rural areas. 
So you see, to paraphrase Mark Twain, reports of the death 
of the RBRVS are greatly exaggerated. But medicine can't 
rely on trust that everything will turn out okay. We must fight 
to preserve the promise of physician payment reform. 
That means opposing policies that will undermine the 
RBRVS (such as a behavioral assumption that would lower 
the fee schedule conversion factor). It means working to 
change policies- such as the ban on reimbursement for EKG 
interpretation - that give with one hand and take away with 
the other. And it means supporting further changes that will 
make the system even better. 
The RBRVS unites physicians under one fair and rational 
payment system to fight future detrimental budget cuts in 
Medicare. Lawmakers faced with a divided house of medicine 
easily can use that division to cut Medicare payments even 
further. But if they're faced with a profession that's united 
under the RBRVS, it won't be easy. 
Support for the RBRVS has been right for our profes-
sion and for our patients. The RBRVS will protect underval-
ued evaluation and management services in an era of Medi-
care budget cutting, increase access and the emphasis on pre-
ventive care for patients, and introduce fairness into the Medi-
care payment system. But we must fight together- as a pro-
fession to make sure it is implemented in the way Congress 
intended. 
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